KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue: 2021

Historic Non-Current Deffered Revenue for Esperion Therapeutics (ESPR) over the last 1 years, with Dec 2021 value amounting to $634,000.

  • Esperion Therapeutics' Non-Current Deffered Revenue fell 80.04% to $211,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $211,000, marking a year-over-year decrease of 80.04%. This contributed to the annual value of $634,000 for FY2021, which is N/A change from last year.
  • Esperion Therapeutics' Non-Current Deffered Revenue amounted to $634,000 in FY2021.
  • Esperion Therapeutics' 5-year Non-Current Deffered Revenue high stood at $634,000 for FY2021, and its period low was $634,000 during FY2021.
  • For the 1-year period, Esperion Therapeutics' Non-Current Deffered Revenue averaged around $634,000, with its median value being $634,000 (2021).